Nicole Hengst
Head of Health Strategies Insights by EVERSANA™
Expertise:
Nicole Hengst leads Health Strategies Insights by EVERSANA™ with the goal of ensuring that all services and interactions exceed client expectations.
Since joining the team, Nicole has led the following services: specialty pharmacies/specialty distributors; health plans and pharmacy benefit managers; national account, regional and Blues Health Plan; and institutional profile. Nicole has also led health economics and outcomes research, risk-based contracting, and the institutional channel suite of services, advising channel strategy development and account management approaches. She is the author of numerous healthcare industry reports and is a frequent contributor to industry trade journals.
Nicole was previously a market research director for Medical Marketing Research International, a firm focusing on key opinion leader identification and segmentation in the U.S. and U.K. markets. She started her career in education, teaching high school biology and chemistry, and was an adjunct professor of algebra and trigonometry at Northampton Community College. Nicole earned a master’s degree in biochemistry and education from East Stroudsburg University.
Articles by Nicole Hengst
30 Years of Insights: A look into the future of research and insights and the need for connectivity to navigate market access challenges
Thirty years ago, the industry faced a new problem: Pharmacy benefit managers were wreaking havoc by negotiating and controlling drug spending with pharmaceutical companies and pharmacies. This resulted in a significant behind-the-scenes impact in determining total drug costs for insurers, shaping patients’ access to medications and determining how much pharmacies were paid. The solution to […]
Considering Commercial Success During Clinical Development: Maintaining a Global Perspective
Although commercial success is the ultimate goal of pharmaceutical research and development (R&D), many new treatments do not meet expectations and fail to achieve broad global reimbursement after initial regulatory approval., This causes therapies to underperform across international markets and, more importantly, limits access for patients in need. For example, only 56% of all new drugs approved by the European Medicines Agency (EMA) […]